Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

C. Kent Osborne, MD
Published: Tuesday, Apr 25, 2017



C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

The NEOSPHERE study showed that adding pertuzumab to trastuzumab (Herceptin) doubled the complete pathological response rate in the neoadjuvant stetting when it was combined with docetaxel.

Pertuzumab was also used in the APHINITY trial, results of which have not been published, but are indicating that pertuzumab provides some additional benefit in the adjuvant setting, says Osborne.
 
SELECTED
LANGUAGE


C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

The NEOSPHERE study showed that adding pertuzumab to trastuzumab (Herceptin) doubled the complete pathological response rate in the neoadjuvant stetting when it was combined with docetaxel.

Pertuzumab was also used in the APHINITY trial, results of which have not been published, but are indicating that pertuzumab provides some additional benefit in the adjuvant setting, says Osborne.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x